Onconetix, Inc.

Name: Onconetix, Inc. standardized financial statements, quarterly
Creator: Listed

ONCONasdaqCIK 1782107HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$17.1k, Q2 FY2026

Operating income−$2.7m, Q2 FY2026

Net income−$2.9m, Q2 FY2026

Onconetix, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	not reported	not reported	0.7	0.7	0.4	0.7	0.1	0.1	0.3	0.3	0.0	0.0
Cost of revenue	$m	not reported	not reported	0.5	0.6	0.3	0.1	0.1	0.0	0.0	0.1	0.0	0.0
Gross profit	$m	not reported	not reported	0.2	0.1	0.1	0.7	0.0	0.1	0.3	0.2	(0.0)	0.0
Research and development	$m	0.2	(0.2)	0.0	not reported	0.1	(0.0)	0.0	not reported	not reported	not reported	not reported	not reported
Selling, general and administrative	$m	4.3	6.4	3.7	2.2	2.6	2.6	1.7	1.5	2.3	1.5	2.0	2.2
Operating income	$m	(4.5)	(22.0)	(11.1)	(13.6)	(2.6)	(29.1)	(12.6)	(1.9)	(2.1)	(1.3)	(10.2)	(2.7)
Interest expense	$m	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.0	0.0	0.0
Income tax	$m	not reported	not reported	(0.1)	0.1	(0.1)	(0.9)	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(5.3)	(22.4)	(11.1)	(14.3)	(3.8)	(29.4)	(8.5)	(2.4)	(8.8)	5.7	(4.2)	(2.9)
Diluted EPS	$ per share	(12.21)	not reported	(20.08)	(2191.59)	(249.08)	not reported	(227.25)	(237.91)	(6.25)	not reported	(6.71)	(1.28)
Basic EPS	$ per share	(12.21)	not reported	(20.08)	(2191.59)	(249.08)	not reported	(227.25)	(237.91)	(6.25)	not reported	(6.71)	(1.28)

Balance sheet

Cash and equivalents$5.9m, Q2 FY2026

Shareholders' equity$13.5m, Q2 FY2026

Onconetix, Inc., balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	period not labelled2025-08-13	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	4.6	4.5	not reported	0.3	0.6	1.6	0.3	0.2	0.8	5.2	3.7	5.9
Current assets	$m	5.8	6.3	2.0	1.0	1.0	2.4	0.9	not reported	1.3	6.1	4.3	6.5
Total assets	$m	87.5	75.0	59.5	61.9	28.2	18.8	19.1	not reported	19.7	24.9	14.8	16.4
Current liabilities	$m	17.2	21.4	20.6	17.4	18.3	14.0	12.7	not reported	16.3	9.1	3.1	2.9
Total liabilities	$m	21.9	25.3	24.0	20.9	18.6	14.3	12.8	not reported	16.3	9.2	3.1	3.0
Shareholders' equity	$m	(5.6)	(21.5)	(35.8)	33.9	8.5	4.0	5.9	not reported	3.4	15.8	11.7	13.5

Cash flow

Operating cash flow−$1.9m, Q2 FY2026

Capital expenditure$3.9k, Q4 FY2024

Onconetix, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(3,040)	(4,312)	(5,232)	(3,200)	(1,147)	(918)	(2,000)	(1,410)	(3,178)	(3,091)	(2,121)	(1,918)
Capital expenditure	$k	0.0	0.0	4.6	17.7	2.3	3.9	not reported	not reported	not reported	not reported	not reported	not reported
Share repurchases	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)2.24m, Q2 FY2026

Onconetix, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	14.3	15.9	15.9	0.4	0.6	0.0	0.0	0.0	0.0	1.4	0.6	2.2

Shares outstanding: 3.95m at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.